DNLI Logo

Denali Therapeutics Inc. (DNLI) 

NASDAQ
Market Cap
$4.22B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
521 of 776
Rank in Industry
282 of 433

Largest Insider Buys in Sector

DNLI Stock Price History Chart

DNLI Stock Performance

About Denali Therapeutics Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of …

Insider Activity of Denali Therapeutics Inc.

Over the last 12 months, insiders at Denali Therapeutics Inc. have bought $0 and sold $7.75M worth of Denali Therapeutics Inc. stock.

On average, over the past 5 years, insiders at Denali Therapeutics Inc. have bought $0 and sold $88.31M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 550,000 shares for transaction amount of $9.9M was made by BRATTON DOUGLAS K (10 percent owner) on 2017‑12‑12.

List of Insider Buy and Sell Transactions, Denali Therapeutics Inc.

2024-11-01Saledirector
3,080
0.0022%
$27.07$83,376+0.59%
2024-10-18SalePresident and CEO
40,000
0.028%
$27.69$1.11M-2.32%
2024-09-30Saledirector
30,000
0.0208%
$29.03$870,900-6.87%
2024-09-13Saledirector
1,020
0.0007%
$30.00$30,600-10.22%
2024-09-03Saledirector
3,080
0.0021%
$25.00$77,007+9.36%
2024-08-21SaleCOFO and Secretary
2,547
0.0018%
$24.78$63,115+7.40%
2024-08-21SaleChief Medical Officer
20,005
0.0137%
$24.57$491,571+7.40%
2024-08-20SalePresident and CEO
2,260
0.0016%
$23.79$53,765+13.53%
2024-08-20SaleCOFO and Secretary
5,806
0.0041%
$23.65$137,286+13.53%
2024-08-20SaleChief Medical Officer
2,453
0.0017%
$23.79$58,357+13.53%
2024-08-20Saledirector
1,727
0.0012%
$23.79$41,085+13.53%
2024-08-13SaleCOFO and Secretary
2,272
0.0016%
$22.89$52,0060.00%
2024-08-13SaleChief Medical Officer
2,337
0.0017%
$22.89$53,4940.00%
2024-07-01Saledirector
3,080
0.0022%
$22.14$68,2040.00%
2024-07-01Saledirector
30,000
0.0212%
$22.12$663,6680.00%
2024-06-13Saledirector
688
0.0005%
$21.79$14,992+13.95%
2024-06-06Saledirector
1,458
0.001%
$21.73$31,682+17.32%
2024-05-15Saledirector
1,674
0.0011%
$20.39$34,133+15.51%
2024-04-15Saledirector
1,666
0.0012%
$18.29$30,471+25.87%
2024-04-01Saledirector
92,500
0.0663%
$20.50$1.9M+7.00%

Insider Historical Profitability

<0.0001%
BRATTON DOUGLAS K10 percent owner
9984836
6.9744%
$29.48112<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Baillie Gifford Co$288.13M9.8514.04M-1.54%-$4.5M0.22
BlackRock$250.34M8.5612.2M+5.69%+$13.47M0.01
The Vanguard Group$225.07M7.6910.97M+1.24%+$2.75M<0.01
Wellington Management Company$169.7M5.88.27M+13.68%+$20.42M0.03
State Street$129.77M4.436.32M+15.27%+$17.19M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.